The ANP32A Knockout Jurkat Polyclonal Cells are a polyclonal population of Jurkat T lymphocytes engineered via CRISPR/Cas9-mediated disruption of the ANP32A gene. This heterogeneous knockout pool provides a loss-of-function model to dissect ANP32A functions in T cell signaling, leukemogenesis, and host?Cpathogen interactions.
Jurkat cells, derived from an acute T cell leukemia patient, serve as a classical model for studying T cell activation, signal transduction, and apoptosis. Their well-characterized signaling networks and genetic tractability make them an ideal host for investigating oncogenic pathways and therapeutic vulnerabilities.
ANP32A (acidic leucine-rich nuclear phosphoprotein 32 family member A) is a multifunctional histone chaperone and potent inhibitor of protein phosphatase 2A (PP2A). It forms a stable complex with the oncoprotein SET to block PP2A-mediated dephosphorylation of AKT and ERK, key kinases in the PI3K and MAPK pathways, thereby sustaining cell survival and proliferation downstream of growth factors and cellular stress. Additionally, ANP32A regulates chromatin dynamics and MYC transcriptional programs, and interacts with HuR and influenza virus polymerase, connecting it to RNA stability and viral replication. Downstream, ANP32A influences caspase-3 activity, histone acetylation, and MYC target gene expression, positioning it at a critical node of oncogenic signaling and host-pathogen interactions.
In the Jurkat T-ALL background, ANP32A disruption is predicted to restore PP2A tumor-suppressor function, leading to decreased AKT and ERK phosphorylation, elevated apoptosis, and reduced MYC-driven proliferation. This knockout model is particularly suited for dissecting the PP2A?CSET?CANP32A regulatory axis in leukemia maintenance and for preclinical evaluation of PP2A-activating drug candidates. Moreover, Jurkat cells?? permissiveness to influenza virus infection makes this system useful for studying ANP32A-dependent viral polymerase activity and host factor requirements.
Key applications include functional genomics of ANP32A in T cell leukemia, mechanistic investigation of PP2A-mediated signaling networks, and target validation for PP2A-directed therapies. Experimental readouts include western blotting and RT-qPCR for knockout confirmation, phospho-specific analysis of pAKT and pERK, flow cytometry?Cbased apoptosis and proliferation assays, co-immunoprecipitation of the SET-PP2A complex, transcriptome profiling via RNA-seq, and influenza virus replication kinetics. This polyclonal knockout pool offers a versatile platform for cancer and virology research. For further information or custom inquiries, please contact Ascent Research.
